We are live on ! Find out more
AIMT

Aimmune Therapeutics
AIMT

Delisted

AIMT was delisted on the 12th of October, 2020.

Back to rankings

0 hedge funds and large institutions have $0 invested in Aimmune Therapeutics in 2020 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 188 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 188 → 0 (-188)

100% less funds holding in top 10

Funds holding in top 10: 9 → 0 (-9)

100% less capital invested

Capital invested by funds: $1.49B → $0 (-$1.49B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 188

Holders
–
Holders Change
-188
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
188
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$143M
2
BlackRock
BlackRock
New York
-$129M
3
PCM
Pentwater Capital Management
Florida
-$86.2M
4
Goldman Sachs
Goldman Sachs
New York
-$75.8M
5
AAM
Alpine Associates Management
Florida
-$71.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
– -$16K -464,696 Closed
CCM
27
Chicago Capital Management
Illinois
– -$14.3M -414,500 Closed
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
28
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
– -$13.8M -400,000 Closed
Public Employees Retirement Association of Colorado
29
Public Employees Retirement Association of Colorado
Colorado
– -$13.7M -396,957 Closed
Balyasny Asset Management
30
Balyasny Asset Management
Illinois
– -$13.4M -388,384 Closed
Temasek Holdings
31
Temasek Holdings
Singapore
– -$11.5M -333,444 Closed
BCM
32
Burrage Capital Management
Massachusetts
– -$11.5M -332,546 Closed
BHMP
33
Bardin Hill Management Partners
New York
– -$10.5M -305,457 Closed
Charles Schwab
34
Charles Schwab
California
– -$10.4M -302,463 Closed
GKIM
35
GW&K Investment Management
Massachusetts
– -$10.2M -295,848 Closed
CS
36
Candriam SCA
Luxembourg
– -$9.05M -262,804 Closed
Two Sigma Advisers
37
Two Sigma Advisers
New York
– -$8.68M -251,800 Closed
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
– -$8.21M -238,307 Closed
IA
39
IndexIQ Advisors
New York
– -$7.89M -229,016 Closed
Bank of New York Mellon
40
Bank of New York Mellon
New York
– -$7.74M -224,805 Closed
PCM
41
Prelude Capital Management
New York
– -$7.58M -219,893 Closed
GI
42
GAMCO Investors
Connecticut
– -$7.38M -214,157 Closed
OP
43
Omni Partners
United Kingdom
– -$7.15M -207,537 Closed
AllianceBernstein
44
AllianceBernstein
Tennessee
– -$7.1M -206,146 Closed
ERSOT
45
Employees Retirement System of Texas
Texas
– -$6.71M -194,804 Closed
N
46
Nuveen
North Carolina
– -$2.25M -178,595 Closed
Bank of America
47
Bank of America
North Carolina
– -$5.79M -168,202 Closed
DCM
48
Dupont Capital Management
Delaware
– -$5.47M -158,783 Closed
PMAM
49
Penn Mutual Asset Management
Pennsylvania
– -$5.47M -158,783 Closed
PAMP
50
Polar Asset Management Partners
Ontario, Canada
– -$5.36M -155,500 Closed
1
2
3 4 5

AIMT Hedge Fund Activity: Q4 2020 in Review

0 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q4 2020, worth a combined $0 — down 100% from $1.49B a quarter earlier.

Sellers outnumbered buyers: 188 funds closed out of AIMT and 0 opened new positions — a net loss of 188 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $143M sold.

  • 0 institutional investors held Aimmune Therapeutics (AIMT) as of Q4 2020, down from 188 in Q3 2020.
  • Funds reported $0 of Aimmune Therapeutics stock for Q4 2020, down 100% quarter-over-quarter.
  • 0 funds opened new Aimmune Therapeutics positions in Q4 2020 and 188 closed out, a net change of -188 holders.
  • The largest Aimmune Therapeutics seller in Q4 2020 was Vanguard Group, an estimated $143M sold.

Based on aggregated 13F filings for Q4 2020.